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WHAT YOU NEED TO KNOW ABOUT 
THE DEADLY OUTBREAK 
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BACKGROUND 
 Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in 
humans.  
 A 27-year-old Belgian microbiologist named Peter Piot and his colleagues were the first to scientifically 
identify the Ebola virus.
 Ebola virus disease (EVD) first appeared in 1976 in 2 simultaneous outbreaks, one in Nzara, Sudan, and 
the other in Yambuku, Democratic Republic of Congo. The latter occurred in a village near the Ebola 
River, from which the disease takes its name.  
 The current outbreak in west Africa, (first cases notified in March 2014), is the largest and most complex 
Ebola outbreak since the Ebola virus was first discovered in 1976. There have been more cases and 
deaths in this outbreak than all others combined. 
  It has also spread between countries starting in Guinea then spreading across land borders to Sierra 
Leone and Liberia, by air (1 traveller only) to Nigeria, and by land (1 traveller) to Senegal.  
 The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past 
outbreaks. 
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What are viral hemorrhagic fevers? 
 Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused 
by several distinct families of viruses. In general, the term "viral 
hemorrhagic fever" is used to describe a severe multisystem syndrome. 
Characteristically, the overall vascular system is damaged, and the body's 
ability to regulate itself is impaired. These symptoms are often 
accompanied by hemorrhage (bleeding). 
 The Special Pathogens Branch (SPB) primarily works with hemorrhagic fever 
viruses that are classified as biosafety level four (BSL-4) pathogens The 
Division of Vector-Borne Infectious Diseases, also in the National Center for 
Infectious Diseases, works with the non-BSL-4 viruses that cause two other 
hemorrhagic fevers, dengue hemorrhagic fever and yellow fever. 
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VHFs are caused 
by viruses of four 
distinct families 
1. They are all RNA viruses, and all are covered, or 
enveloped, in a fatty (lipid) coating. 
2.     Their survival is dependent on an animal or 
insect host, called the natural reservoir. 
3.     The viruses are geographically restricted to the 
areas where their host species live. 
4.     Humans are not the natural reservoir for any of 
these viruses. Humans are infected when they 
come into contact with infected hosts. However, 
with some viruses, after the accidental 
transmission from the host, humans can transmit 
the virus to one another. 
5.     Human cases or outbreaks of hemorrhagic 
fevers caused by these viruses occur sporadically 
and irregularly. The occurrence of outbreaks 
cannot be easily predicted. 
6.     With a few noteworthy exceptions, there is no 
cure or established drug treatment for VHFs. 
 
VHFs 
Arenaviruses 
Bunyaviruses 
Flaviviruses 
Filoviruses 
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SPECIES GENUS FAMILY 
Filoviridae 
Ebolavirus 
Zaire 
Bundibugyo 
Sudan 
Reston 
Taï Forest 
Cuevavirus 
Marburgvirus 
LARG 
OUTBREAK 
IN AFRICA 
2014 
The current outbreak 
in west Africa, (first 
cases notified in March 
2014), is the largest 
and most complex 
Ebola outbreak since 
the Ebola virus was first 
discovered in 1976.  
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Host-Virus Interaction 
Inhibition of host Interferon induction  
Vp35 protein prevents host interferon    
induction . 
Inhibition of host interferon signalling 
 Vp24 protein block interferon signaling 
 
Antigenic subvertion                     
 Small Glycoprotein (sGP) is a secreted     
truncated version of GP that prevent host 
antibodies anti-GP to effectively neutralize 
it. 
 
Inhibition of acquired immune response 
Ebolavirus may encode for a  
superantigen, thereby inhibiting Vbeta T 
cells . 
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Replication Cycle 
• Ebola is a filamentous, single-
stranded RNA virus with an 
unusual, variable-length, 
branched morphology. The 
helical capsid is enclosed inside 
a membrane. 
• the viral RNA polymerase (L 
protein) begins to copy the (-) 
strand RNA to make (+) strand 
transcripts that mimic the 
structure of mRNA and are 
translated by host ribosomes. 
• The rest of the replicative cycle is 
unclear, but probably involves 
assembly of the viral RNA at the 
host membrane and budding of 
the helical virus from the cell. 
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EBOLA PATHOGENESIS 
Primary infection and 
circulation 
Ebola virus infects 
subjects through 
contact with body 
fluid or secretions 
from an infected 
patient and is 
distributed through 
the circulation.  
 
 
 
 
 
 
 
 
Secondary spread of 
virus 
Early targets of 
replication are 
reticuloendothelial 
cells, with high 
replication in 
several cell types 
within the lungs, 
liver and spleen. 
Targets of cytotoxicity 
Dendritic cells, 
macrophages and 
endothelium appear to 
be susceptible to 
cytopathic effects of 
Ebola virus gene 
Indirect damage may 
also be inflicted by 
circulating factors such 
as tumor necrosis factor 
and nitric oxide. 
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IMMUNE RESPONSES 
 Envelope GP enables viral binding and entry into host 
macrophages and dendritic cells.  
  The infected macrophage is no longer able to 
phagocytize invading virus particles, but instead serves 
as a viral production factory.  
  As macrophages travel throughout the body, the virus 
spreads far and wide.  Furthermore, the macrophage 
also releases cytokines in response to viral invasion.  
  Excessive endothelial permeability is further 
exacerbated by the circulating cytokines.  resulting 
ultimately in hemorrhage and hypovolemic shock.   
 Initially, it's the cytokine storm that kills you .  
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TRANSMISSON 
 
 It is thought that fruit bats of the Pteropodidae family are natural Ebola virus hosts. 
  Ebola is introduced into the human population through close contact with the 
blood, secretions, organs or other bodily fluids of infected animals such as 
chimpanzees, gorillas, fruit bats, monkeys, forest antelope and porcupines found ill or 
dead or in the rainforest. 
 Ebola then spreads through human-to-human transmission via direct contact 
(through broken skin or mucous membranes) with the blood, secretions, organs or 
other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, 
clothing) contaminated with these fluids. 
 Health-care workers have frequently been infected while treating patients with 
suspected or confirmed EVD. 
 Burial ceremonies in which mourners have direct contact with the body of the 
deceased person can also play a role in the transmission of Ebola. 
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Prevention and control 
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Prevention and control 
Good outbreak control relies on applying a package of interventions, namely case 
management, surveillance and contact tracing, a good laboratory service, safe burials 
and social mobilisation. Community engagement is key to successfully controlling 
outbreaks. 
Risk reduction messaging should focus on several factors: 
Reducing the risk of                  
wildlife-to-human transmission 
 From contact with infected 
fruit bats or monkeys/apes 
and the consumption of 
their raw meat. Animals 
should be handled with gloves 
and other appropriate 
protective clothing. Animal 
products (blood and meat) 
should be thoroughly cooked 
before consumption. 
 
 
 
 
 
 
 
 
 
 
 
Reducing the risk of human-to-
human transmission 
From direct or close contact with 
people with Ebola symptoms, 
particularly with their bodily fluids. 
Gloves and appropriate personal 
protective equipment should be 
worn when taking care of ill patients 
at home. Regular hand washing 
is required after visiting patients in 
hospital, as well as after taking care 
of patients at home. 
Outbreak containment 
measures 
 Including prompt and safe burial 
of the dead, identifying people who 
may have been in contact with 
someone infected with Ebola, 
monitoring the health of contacts 
for 21 days, the importance of 
separating the healthy from the sick 
to prevent further spread, the 
importance of good hygiene and 
maintaining a clean environment. 
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CONTROLLING INFECTION IN HEALTH-CARE SETTINGS 
 Health-care workers caring for patients with suspected or confirmed Ebola virus should apply extra infection 
control measures to prevent contact with the patient’s blood and body fluids and contaminated surfaces or 
materials such as clothing and bedding.  
 When in close contact (within 1 metre) of patients with EBV, health-care workers should wear face protection (a 
face shield or a medical mask and goggles), a clean, non-sterile long-sleeved gown, and gloves (sterile gloves for 
some procedures). 
 Laboratory workers are also at risk. Samples taken from humans and animals for investigation of Ebola infection 
should be handled by trained staff and processed in suitably equipped laboratories. 
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A Quarantine separates healthy people 
who are at risk of developing a disease 
to wait and see if they get sick,Isolation 
separates sick people who are 
contagious from healthy people, to stop 
them from spreading their disease. 
 
Family members would be allowed to 
stay with the person being quarantined. 
Friends would also be allowed to visit. 
 
This protective measure is too 
important to be voluntary. 
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Laboratory Findings 
• Low white blood cell and platelet counts and  
• Liver enzyme tests show elevated AST and ALT. 
•  serum levels of pro-inflammatory cytokines rise. 
• Urine tests show proteinuria. 
• Blood  tests often indicate leukopenia, thrombocytopenia, and 
hyperproteinemia. 
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Diagnosis 
 
• It can be difficult to distinguish EVD from other infectious diseases such as 
malaria, typhoid fever and meningitis. Confirmation that symptoms are 
caused by Ebola virus infection are made using the following 
investigations: 
1. antibody-capture enzyme-linked immunosorbent assay (ELISA) 
2. antigen-capture detection tests 
3. serum neutralization test 
4. reverse transcriptase polymerase chain reaction (RT-PCR) assay 
5. electron microscopy 
6. virus isolation by cell culture 
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• Symptoms of Ebola and complications are treated as they appear. The following basic 
interventions, when used early, can significantly improve the chances of survival: 
1.  Providing intravenous fluids (IV) and balancing electrolytes (body salts).  
2. Maintaining oxygen status and blood pressure. 
3. Treating other infections if they occur. 
• There is as yet no proven treatment available for EVD. However, a range of potential 
treatments including blood products, immune therapies and drug therapies are currently 
being evaluated. 
•  No licensed vaccines are available yet, but 2 potential vaccines are undergoing 
human safety testing. 
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• Supportive care-rehydration with oral or intravenous fluids- and treatment of 
specific symptoms, improves survival. There is as yet no proven treatment 
available for EVD. However, a range of potential treatments including blood 
products, immune therapies and drug therapies are currently being evaluated. 
•  No licensed vaccines are available yet, but 2 potential vaccines are 
undergoing human safety testing. 
by: Gelareh Nasiri / Dr M.Aslanimehr 31 
EBOLA VACCINES 
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